Evidence map›Paper›PMID 39885469›Full record

ArticleBMC cancer2025

Serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with breast cancer attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Muluabay Getie, Biset Asrade Mekonnen, Daniel Seifu, Yonas Mulugeta, Solomon Tebeje, Chernet Tafere, Asmare Amuamuta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muluabay GetieDepartment of Biomedical Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, P.O. Box 79, Ethiopia.
Biset Asrade MekonnenDepartment of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, P. O. Box 79, Ethiopia. biset2006me@gmail.com.
Daniel SeifuDepartment of Biochemistry, School of Medicine, University of Global Health Equity, Kigali, P.O. Box 6955, Rwanda.
Yonas MulugetaDepartment of Biomedical, College of Health Science, Arsi University, Asella, P. O. Box 193, Ethiopia.
Solomon TebejeDepartment of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, P. O. Box 1176, Ethiopia.
Chernet TafereDepartment of Pharmacy, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, P. O. Box 79, Ethiopia.
Asmare AmuamutaDepartment of Biomedical Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, P.O. Box 79, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy is a well-established therapeutic approach for several malignancies, including breast cancer (BCa). However, the clinical efficacy of this drug is limited by cardiotoxicity. Assessing multiple cardiac biomarkers can help identify patients at risk of adverse outcomes from chemotherapy.

objectiveTo evaluate changes in serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with BCa attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

methodsAn experimental study design was used. Forty patients with breast cancer were selected using a convenience sampling method. After obtaining informed consent, 40 paired samples (40 samples before chemotherapy and 40 matched samples after three cycles of chemotherapy) were collected between May 2018 and March 2019. An Elecsys 2010 Troponin-T immunoassay analyzer was used to measure serum levels of cardiac troponin T (cTnT), creatinine kinase-myocardial band (CK-MB), C-reactive protein (CRP), and R and D systemic luminex performance assays were used to measure serum Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF- α). Data were analyzed using the SPSS version 23 package, and a p-value < 0.05 was considered statistically significant.

resultsAmong female patients with BCa receiving chemotherapy, 20%, 15%, and 35% of patients had elevated cTnT, CK-MB, and CRP levels, respectively, after three cycles of chemotherapy. In contrast, 15% of patients had baseline elevated CRP levels compared with their respective cutoff values. The mean serum cTnT, CK-MB, CRP, and TNF-α levels significantly increased (p < 0.05) compared with their respective baseline values. However, the IL-6 levels at baseline and after chemotherapy were not significantly different.

conclusionThis study revealed significant increases in cardiac and inflammatory biomarkers following chemotherapy among female patients with breast cancer in the study area. Therefore, cardiac biomarkers and echocardiography findings were used to assess functional abnormalities and treatment outcomes.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCardiotoxicityAdultAgedBiomarkersC-Reactive ProteinCreatine Kinase, MB FormEthiopiaFemaleHumansInterleukin-6Middle AgedTroponin TTumor Necrosis Factor-alphaBiomarkersC-Reactive ProteinCreatine Kinase, MB FormInterleukin-6Troponin TTumor Necrosis Factor-alphaBreast cancerCardiac biomarkersCardiotoxicityChemotherapyInflammatory markers

Identifiers

PMID39885469
PMCPMC11783745

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.